Serum Levels of miR-223-3p and miR-223-5p in Prostate Diseases

MicroRNA ◽  
2020 ◽  
Vol 09 ◽  
Author(s):  
Yakup Dülgeroğlu ◽  
Onur Eroğlu
Keyword(s):  
Prostate Cancer ◽  
Specific Antigen ◽  
Serum Levels ◽  
Diagnostic Value ◽  
Serum Samples ◽  
Prostate Hyperplasia ◽  
Significant Difference ◽  
Prostate Cancer Development ◽  
New Biomarkers ◽  
Prostate Diseases

Introduction: Prostate cancer (PCa) is the second most common cancer in males and is at fifth place in cancerassociated mortality. Although the prostate-specific antigen (PSA) test is widely used in PCa screenings, it has significant limitations in the differential diagnosis of PCa. Therefore, studies on developing new biomarkers on PCa diagnosis are ongoing. miRNAs are good candidate biomarkers for the diagnosis of cancers, including prostate cancer, as they can be easily detected from the circulation. Objective: In this study, it is aimed to determine diagnostic value of serum levels of miR-223-3p and -223-5p in benign prostate hyperplasia (BPH), chronic prostatitis (CP) and prostate cancer (PCa). Methods: Serum samples was collected from 68 patients in total (25 BPH, 10 CP, 33 PCa). miR-223-3p and -223-5p levels were measured in serum with qRT-PCR. The Ct values of miRNAs were normalized according to the Ct value of ce-miR-39 and calculated -ΔCt values were used statistical analyses. Results: The serum levels of miR-223-3p and -223-5p were downregulated in the PCa and CP groups, compared to the BPH group. There was no statistically significant difference between PCa and CP groups. The sensitivity and specificity of miR-223-3p, -223-5p and their combination were calculated as 88% and 88%; 86% and 79%; 93% and 92% in discriminating BPH and PCa groups, respectively. Conclusion: In this study, it was shown that miR-223-3p and -223-5p were both detectable in the circulation. miR-223- 3p, -223-5p, and their combination may be good candidate biomarkers for prostate cancer diagnosis. Also, observation of similar serum levels of miR-223-3p and -223-5p between CP and PCa groups suggests that miR-223 may play a role in prostate cancer development originated from chronic inflammation.

Clinical competence of serum miR-372 expression in diagnosing prostate cancer

2020 ◽  
Author(s):  
Sheng Li ◽  
Xiaolan Ruan ◽  
Tongzu Liu
Keyword(s):  
Prostate Cancer ◽  
Expression Patterns ◽  
Specific Antigen ◽  
Diagnostic Value ◽  
Positive Lymph Node ◽  
Operating Characteristics ◽  
Serum Samples ◽  
Diagnostic Significance ◽  
Aberrant Expression ◽  
Poor Outcomes

Abstract Background: Prostate cancer (PCa) is considered as a serious healthy burden among males around the world. The limited diagnosis leads to poor outcomes of this malignancy. Aberrant expression of microRNAs (miRNAs) have been found in human cancers and play crucial roles in these malignant diseases. MicroRNA-372 (miR-372), as a type of miRNAs, has ever been investigated in various cancers. The purpose of the present study was to assess the expression patterns and diagnostic value of miR-372 in patients with PCa.Methods: 134 PCa patients and 68 healthy individuals were included in this study. The serum expression of miR-372 was examined by quantitative real-time PCR (qRT-PCR). To verify the diagnostic significance of miR-372, receiver operating characteristics (ROC) analysis was conducted for PCa patients.Results: Downregulated miR-372 expression was detected in serum samples collected from PCa patients compared with the healthy controls (P<0.001). The decreased expression of miR-372 was influenced by the positive lymph node metastasis (P=0.016), high prostate-specific antigen (PSA) concentration (P=0.002) and advanced TNM stage (P=0.013). The ROC curve was obtained with an AUC value of 0.896. At the cutoff value of 2.855, the sensitivity and specificity were 82.8% and 87.3%, respectively, suggesting the high diagnostic accuracy of miR-372.Conclusion: In summary, serum downregulated expression of miR-372 could serve as an efficient diagnostic biomarker for patients with PCa.

What is the role of microRNA-301A expression as a diagnostic and predictive marker of biochemical recurrence for prostate cancer?

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 19-19
Author(s):  
Adnan Dervishi ◽  
Samarpit Rai ◽  
Kristy Doan Nguyen ◽  
Thomas Michael FitzGibbon ◽  
Paul Knoll ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Biochemical Recurrence ◽  
Clinical Decision Making ◽  
Specific Antigen ◽  
Predictive Marker ◽  
Clinical Decision ◽  
Definitive Treatment ◽  
Serum Samples ◽  
Prostate Hyperplasia

19 Background: Prostate specific antigen (PSA) screening for prostate cancer (PCa) remains controversial, due to its association with an increase in overdiagnosis of clinically insignificant PCa, and overtreatment. Hence, the need for more specific biomarkers to detect PCa and determine its prognosis. MicroRNA expression has previously been demonstrated as a biomarker to detect several malignancies. Studies suggest that microRNA-301a (miR-301a) inhibits the pro-apoptotic function of RUNX3, a transcription factor, and consequently activates ROCK1-mediated survival signaling in PCa. This study establishes the role of miR-301a as a reliable biomarker that can distinguish between patients with benign prostate hyperplasia (BPH) and PCa, and predict biochemical recurrence (BCR) after definitive treatment of PCa. Methods: Serum samples and tissue from prostate biopsies were collected from patients with an elevated PSA prospectively. The expression of miR- 301a was measured via reverse transcriptase-polymerase chain reaction. Additionally, miR-301a expression was retrospectively evaluated in prostatic tissue of 50 patients with PCa, including benign tissue, and correlated with clinico-pathological characteristics to predict BCR. Immunohistochemistry was performed to confirm the molecular target of miR-301a in cancerous tissue. Results: miR-301a demonstrated a significantly higher expression (p = 0.013) in both PCa tissue (Gleason 6 & 7 PCa) and serum samples (p = 0.011) when compared to BPH. Expression of miR-301a in Gleason 6 & 7 prostatectomy specimens positively correlated with patients who developed BCR when compared to patients who did not. When compared to the current nomogram for the prediction of PCa (i.e., PSA, age, race, Gleason score, and family history), incorporation of miR-301a was associated with a superior prediction of BCR at three years post-prostatectomy. Conclusions: miR-301a expression is a valuable tool for diagnosing PCa in patients with an elevated PSA. Combining miR-301a with PSA is associated with better risk stratification of PCa patients, and may help facilitate clinical decision making.

scholarly journals Infection with Human Papillomavirus as a Potential Risk Factor for Prostate Cancer: A Case-Control Study

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Solmaz Ohadian Moghadam ◽  
Mohammad Reza Nowroozi ◽  
Ali Nowroozi ◽  
Pouria Rezaei
Keyword(s):  
Prostate Cancer ◽  
Human Papillomavirus ◽  
High Risk ◽  
Case Control Study ◽  
Specific Antigen ◽  
Hpv Infection ◽  
Case Control ◽  
Prostate Hyperplasia ◽  
Significant Difference ◽  
Control Study

Background: Prostate cancer is one of the most frequent cancers in men, with several risk factors, including infection. In this study, we aimed to assess the association of human papillomavirus (HPV) infection with prostate cancer risk and aggressiveness. Methods: This case-control study was performed on a total of 70 archival formalin-fixed paraffin-embedded (FFPE) prostatic tissue blocks. Among them, 35 histopathologically confirmed prostate cancer tissues and 35 benign prostate hyperplasia (BPH) samples were enrolled as cases and controls, respectively. The specimens were examined by the polymerase chain reaction (PCR) and in situ hybridization for the detection of HPV DNA of both low-risk (6, 11) and high-risk (16, 18) types. Results: The primary results of PCR for the L1 region revealed HPV infection in 34.3% and 8.6% of the cases and controls, respectively (P = 0.018). The HPV typing using hybridization revealed a significant difference between the two groups in terms of infection with HPV types 16 and 18 (P = 0.003, P = 0.028, respectively). The findings showed no significant association of HPV infection with age and prostate specific antigen (PSA) level of the patients. In addition, no significant association was found between infection with HPV and Gleason score (GS). Conclusions: Our findings indicated that HPV infection, especially with high-risk types 16 and 18, has a significant association with prostatic carcinogenesis. In addition, although patients with GS = 7 showed higher rates of infection with HPV, we did not observe any statistical association between HPV infection and GS.

scholarly journals Netrin 1 and Alpha-Methyl Acylcoenzim-A Racemase in diagnosis of prostate cancer

2018 ◽  
Vol 49 (2) ◽  
pp. 164-168
Author(s):  
Ersin Koseoglu ◽  
Altug Tuncel ◽  
Melih Balci ◽  
Oguzhan Kaya ◽  
Yilmaz Aslan ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Specific Antigen ◽  
Transrectal Ultrasound ◽  
Prostate Hyperplasia ◽  
Cancer Group ◽  
Significant Difference ◽  
Blood And Urine Samples ◽  
Urine Levels ◽  
Group Serum ◽  
Serum And Urine

Objectives: To investigate serum and urine levels of Alphamethylacyl-CoA-racemase (AMACR) and Netrin 1 in patients with and without prostate cancer and to determine whether these markers could be used as alternatives in diagnosis of prostate cancer instead of serum prostate specific antigen (PSA) levels. Methods: One hundred and seventy five patients between 45-75 years to whom transrectal ultrasound guided biopsies were performed for abnormal serum PSA levels or digital rectal examinations were included. The levels of AMACR and Netrin 1 levels of blood and urine samples of 5 mL those were taken prior to biopsies were measured. Results: The mean age of the patients was 62.7 ±6.4 years. Prostate cancer was detected in 40 patients (22.8%) while 135 of them (77.2%) were diagnosed as benign prostate hyperplasia (BPH). In BPH group, serum and urine levels of AMACR and Netrin 1 were 13.4 ±16.9 ng/mL; 7.1 ±3.4 ng/mL; 164.1 ±46 pg/mL and 19.5±5 pg/mL respectively. The levels of serum and urine levels of AMACR and Netrin 1 were 10.2 ±9.8 ng/mL; 6.8 ±2.5 ng/mL; 159.1 ±44.1 pg/mL and 20.1 ±5.3 pg/mL respectively in prostate cancer group. There was no statistically significant difference or correlation between these two groups serum and urine AMACR and Netrin 1 results Conclusions: Serum and urine levels of AMACR and Netrin 1 were not found to be alternatives for serum PSA levels in the diagnosis of prostate cancer in this study.

Clinical Utility of Prostatic Specific Antigen and Prostatic Acid Phosphatase Serum Levels in Monitoring Prostate Cancer

1988 ◽  
Vol 3 (1) ◽  
pp. 23-28 ◽  
Author(s):  
J. Morote ◽  
A. Ruibal ◽  
J. Palou ◽  
J. A. de Torres ◽  
A. Soler-Roselló
Keyword(s):  
Prostate Cancer ◽  
Acid Phosphatase ◽  
Specific Antigen ◽  
Prostatic Acid Phosphatase ◽  
Serum Levels ◽  
Response To Treatment ◽  
Prostatic Specific Antigen ◽  
Serum Samples ◽  
Better Than

We analysed 696 prostatic specific antigen (PSA) and prostatic acid phosphatase (PAP) serum samples by double antibody radioimmunoassay (RIA) I125 in the follow-up of 122 patients with prostate cancer under treatment. PSA levels were significantly correlated to response to treatment, whereas PAP results did not differentiate patients with partial or complete remission. Progression of the disease was detected in 95.2 and 85.4% of PSA and PAP samples, and increased to 99.9% using both simultaneously. On the whole, PSA was better than PAP in monitoring prostate cancer, and the efficacy was greater using both markers together.

scholarly journals Comparative Assessment of the Diagnostic Performance of PCA3 in Urinary Sediments and Exosomes for Prostate Cancer in Chinese Population with the Total PSA range of 4-10 ng/ml.

2020 ◽  
Author(s):  
Zhenqiang Fang ◽  
Fan He ◽  
Huan Feng ◽  
Weishen Jia ◽  
Mengjia Sun ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Roc Analysis ◽  
Specific Antigen ◽  
Diagnostic Value ◽  
Chinese Patients ◽  
Current Evidence ◽  
Urine Sediment ◽  
Total Prostate Specific Antigen ◽  
Significant Difference ◽  
Total Psa

Abstract Background: The diagnostic value of prostate cancer antigen-3 (PCA3) in urine sediment and exosome in Chinese patients with total prostate specific antigen (PSA) ranging from 4-10ng/ml.Methods: Serum and urine samples were collected from consecutive eligible patients. The PCA3 and PSA mRNA were tested by quantitative real-time PCR. Results: Overall 130 patients were involved in this study. 113 cases in urinary sediments group and 103 cases in urinary exosomes group were finally analyzed. 24 of 130 patients (18.5%), 20 of 113 patients (17.7%) and 17 of 103 patients (16.5%) were diagnosed as PCa in the three groups, respectively. The PCA3 score and PSAD of patients with positive biopsy results were significantly higher than those with negative biopsy results in both the urinary sediments and exosomes groups, but no differences between two urinary substrates groups. The ROC analysis showed the higher values of AUC of the PCA3 score in urinary sediments and exosomes than that of serum PSA (0.728 vs 0.540, P = 0.0402; 0.740 vs 0.540, P = 0.0263), but no significant difference in term of AUC of PCA3 between two urinary substrates groups (0.728 vs 0.740, P = 0.9000), as well as when compared the AUC of the PCA3 score with that of %fPSA and PSAD (P > 0.05).Conclusion: The current evidence suggests that diagnostic performances of PCA3 in urinary sediments and exosomes were not significant different, but both were superior to serum PSA in Chinese patients with PSA 4–10ng/ml.

scholarly journals Utility of a Fifth-Generation Ultrasensitive Prostate-Specific Antigen Assay for Monitoring Prostate Cancer Patients after Radical Prostatectomy with 3 Years of Follow-Up

2020 ◽  
Vol 66 (10) ◽  
pp. 1329-1338
Author(s):  
Annie H Ren ◽  
Antoninus Soosaipillai ◽  
Anu Mathew ◽  
Galina Nikolenko ◽  
Laukik Sardesai ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Prostate Specific Antigen ◽  
Limit Of Detection ◽  
Specific Antigen ◽  
Serum Samples ◽  
Psa Kinetics ◽  
Fifth Generation ◽  
Low Concentrations ◽  
Significant Difference

Abstract Background We investigated an ultrasensitive prostate-specific antigen (uPSA) immunoassay (MesoScale; lower limit of detection (LLD) of 0.0035 pg/mL) to monitor patients with prostate cancer (PCa) following radical prostatectomy (RP) and to examine whether changes in PSA in the conventionally undetectable range (&lt;1 pg/mL) can predict biochemical relapse (BCR). Methods We measured uPSA in serial serum samples (N = 100) collected from 20 RP cases with a third-generation ELISA (LLD of 1 pg/mL) and the fifth-generation MesoScale assay. We analyzed the PSA nadir changes to classify patients into BCR or non-BCR groups, observed the trends in PSA kinetics, and associated BCR status with clinicohistopathological features. Results The ELISA could quantify PSA in only 38% of the RP samples, detecting BCR in 7 of 20 patients with PCa. The MesoScale assay quantified PSA in all samples, showing 8 of 20 patients with BCR. However, there was no significant difference between the median time to BCR detection based on ELISA (1016 days) compared with MesoScale data (949 days). Gleason scores were higher in the BCR groups compared with non-BCR. There was no significant difference for other clinicohistopathological parameters. Conclusions The uPSA MesoScale technology could track miniscule changes in serum PSA in the range of 0.003–1 pg/mL in all RP cases. However, PSA kinetics and nadir at concentrations &lt;2 pg/mL fluctuated, and increases below this range could not reliably suggest signs of BCR. Instead, ultrasensitive fifth-generation PSA assays may hold clinical potential for measuring the low concentrations of PSA in women for various medical contexts.

scholarly journals Diagnostic Value of Platelet–To-Lymphocyte Ratio in Prostate Cancer

2019 ◽  
Vol 7 (7) ◽  
pp. 1093-1096 ◽  
Author(s):  
Kharisma Prasetya Adhyatma ◽  
Syah Mirsya Warli
Keyword(s):  
Prostate Cancer ◽  
Cancer Risk ◽  
Prostate Volume ◽  
Specific Antigen ◽  
Prostate Cancer Risk ◽  
Diagnostic Value ◽  
Significant Difference ◽  
Diagnostic Values ◽  
Absolute Lymphocyte Counts ◽  
The Relationship

BACKGROUND: Previous studies demonstrated the promising value of platelet-to-lymphocyte (PLR) in prostate cancer. AIM: This study was conducted to evaluate its pre-biopsy values in predicting prostate cancer. METHODS: We included all benign prostatic hyperplasia (BPH) and prostate cancer (PCa) patients who underwent a prostate biopsy in Adam Malik Hospital between August 11th 2011 and August 31st 2015. The relationship between pre-biopsy variables which could be affecting the percentage of prostate cancer risk was evaluated, including age, prostate-specific antigen (PSA) level, and prostate volume (EPV). The PLR was calculated from the ratio of related platelets with their absolute lymphocyte counts. The values then analysed to evaluate their associations with the diagnosis of BPH and PCa. RESULTS: As many as 298 patients consisted of 126 (42.3%) BPH and 172 PCa (57.7%) patients are included in this study. Mean age for both groups are 66.36 ± 7.53 and 67.99 ± 7.48 years old (p = 0.64), respectively. There are statistically significant differences noted from PSA (19.28 ± 27.11 vs 40.19 ± 49.39), EPV (49.39 ± 23.51 vs 58.10 ± 30.54), PLR (160.27 ± 98.96 vs 169.55 ± 78.07), and NLR (3.57 ± 3.23 vs 4.22 ± 2.59) features of both groups (p < 0.05). The AUC of PLR is 57.9% with a sensitivity of 56.4% and specificity of 55.6% in the cut-off point of 143 (p = 0.02). Besides, the NLR cut-off point of 3.08 gives 62.8% AUC with 64.5% sensitivity and 63.5% specificity. We asked for permission from the preceding authors of Indonesian Prostate Cancer Risk Calculator (IPCRC) and calculated its value from 98 randomised patients consist of 45 (45.92%) BPH and 53 (54.08%) PCa. We found a comparable value between PLR/NLR with IPCRC in predicting prostate cancer (AUC of 67.6%, 75.3%, and 68.4%, respectively) with a statistically significant difference of all value in both groups (p < 0.05). CONCLUSIONS: PLR gives promising value in predicting prostate cancer in suspected patients. We suggest a further prospective study to validate its diagnostic values so it can be used as applicable routine calculation.

scholarly journals Reassessing the Role of the Active TGF-β1 as a Biomarker in Systemic Sclerosis: Association of Serum Levels with Clinical Manifestations

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Andréa Tavares Dantas ◽  
Sayonara Maria Calado Gonçalves ◽  
Anderson Rodrigues de Almeida ◽  
Rafaela Silva Guimarães Gonçalves ◽  
Maria Clara Pinheiro Duarte Sampaio ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Clinical Manifestations ◽  
Serum Levels ◽  
Vascular Involvement ◽  
Digital Ulcers ◽  
Serum Samples ◽  
Peripheral Blood Mononuclear ◽  
Pbmc Culture ◽  
Significant Difference ◽  
Skin Biopsies

Objective. To determine active TGF-β1 (aTGF-β1) levels in serum, skin, and peripheral blood mononuclear cell (PBMC) culture supernatants and to understand their associations with clinical parameters in systemic sclerosis (SSc) patients.Methods. We evaluated serum samples from 56 SSc patients and 24 healthy controls (HC). In 20 SSc patients, we quantified spontaneous or anti-CD3/CD28 stimulated production of aTGF-β1 by PBMC. The aTGF-β1 levels were measured by ELISA. Skin biopsies were obtained from 13 SSc patients and six HC, and TGFB1 expression was analyzed by RT-PCR.Results. TGF-β1 serum levels were significantly higher in SSc patients than in HC (p< 0.0001). Patients with increased TGF-β1 serum levels were more likely to have diffuse subset (p= 0.02), digital ulcers (p= 0.02), lung fibrosis (p< 0.0001), positive antitopoisomerase I (p= 0.03), and higher modified Rodnan score (p= 0.046). Most of our culture supernatant samples had undetectable levels of TGF-β1. No significant difference in TGFB1 expression was observed in the SSc skin compared with HC skin.Conclusion. Raised active TGF-β1 serum levels and their association with clinical manifestations in scleroderma patients suggest that this cytokine could be a marker of fibrotic and vascular involvement in SSc.

scholarly journals Prognostic role of docetaxel-induced suppression of free testosterone serum levels in metastatic prostate cancer patients

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Paula Kappler ◽  
Michael A. Morgan ◽  
Philipp Ivanyi ◽  
Stefan J. Brunotte ◽  
Arnold Ganser ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Metastatic Prostate Cancer ◽  
Cox Regression ◽  
Specific Antigen ◽  
Progression Free Survival ◽  
Serum Levels ◽  
Biologically Active ◽  
Free Form ◽  
Total Testosterone ◽  
The Impact

AbstractTo date, only few data concerning the biologically active, free form of testosterone (FT) are available in metastatic prostate cancer (mPC) and the impact of FT on disease, therapy and outcome is largely unknown. We retrospectively studied the effect of docetaxel on FT and total testosterone (TT) serum levels in 67 mPC patients monitored between April 2008 and November 2020. FT and TT levels were measured before and weekly during therapy. The primary endpoint was overall survival (OS). Secondary endpoints were prostate-specific antigen response and radiographic response (PSAR, RR), progression-free survival (PFS), FT/TT levels and safety. Median FT and TT serum levels were completely suppressed to below the detection limit during docetaxel treatment (FT: from 0.32 to < 0.18 pg/mL and TT: from 0.12 to < 0.05 ng/mL, respectively). Multivariate Cox regression analyses identified requirement of non-narcotics, PSAR, complete FT suppression and FT nadir values < 0.18 pg/mL as independent parameters for PFS. Prior androgen-receptor targeted therapy (ART), soft tissue metastasis and complete FT suppression were independent prognostic factors for OS. FT was not predictive for treatment outcome in mPC patients with a history of ART.

Sign in / Sign up

Export Citation Format

Share Document